dc.contributor.author | Pinto Paz, Mirian Elizabeth | |
dc.contributor.author | Cotrina Concha, Jose Manuel | |
dc.contributor.author | Benites Zapata, Vicente A. | |
dc.date.accessioned | 2023-03-23T22:00:22Z | |
dc.date.available | 2023-03-23T22:00:22Z | |
dc.date.issued | 2021-01 | |
dc.identifier.citation | Cancer Treatment and Research Communications. 2021;29. | es_PE |
dc.identifier.issn | 2468-2942 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12959/3509 | |
dc.description.abstract | Introduction: Cutaneous malignant melanoma (CMM) incidence has risen rapidly in the last 50 years. Poor progression and high mortality characterize CMM, making a thorough understanding of progression and associated factors essential for optimizing care.
Aims: We assessed the association between the Neutrophil-to-Lymphocyte Ratio (NLR) and mortality in adults with CMM from an entirely mixed-race Hispanic population during 12 consecutive years of extensive follow-up.
Material & Methods: We performed a retrospective cohort study in a tertiary hospital in Peru. NLR was categorized with a cutoff value higher or equal than 3. We collected demographic variables, laboratory results and treatments at baseline of follow-up. Cox regression analysis was performed, and we calculated crude and adjusted hazard ratios (HR) and their 95% confidence interval (95%CI).
Results: The analysis was from 615 CMM cases, and there were 378 deaths. Most melanomas (63.6%) were acral lentiginous. The crude analysis showed that high NLR is a risk factor for mortality, HR = 2.52; 95%CI (2.03–3.14). High NRL ratio remains statistically significant after adjusting for confounding variables, aHR = 1.61; 95%CI (1.16–2.24). Other risk factors for mortality were clinical stages III and IV, older than 60 years, females and greater Breslow thickness.
Conclusions: We concluded that high NRL ratio is a risk factor for mortality and should be monitored in every patient who is diagnosed with malignant melanoma during their first blood count. It should then be carried out in follow-up controls for patients of clinical stage III and IV only, or in patients who present a relapse. | es_PE |
dc.format | application/pdf | es_PE |
dc.language.iso | eng | es_PE |
dc.publisher | Elsevier | es_PE |
dc.relation.uri | https://www.sciencedirect.com/science/article/pii/S246829422100160X | es_PE |
dc.rights | info:eu-repo/semantics/openAccess | es_PE |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0/ | es_PE |
dc.subject | Cutaneous malignant melanoma | es_PE |
dc.subject | Neutrophil-lymphocyte ratio | es_PE |
dc.subject | Prognosis | es_PE |
dc.subject | Progression | es_PE |
dc.subject | Melanoma maligno cutáneo | es_PE |
dc.subject | Relación neutrófilos-linfocitos | es_PE |
dc.title | Mortality in cutaneous malignant melanoma and its association with Neutrophil-to-Lymphocyte ratio | es_PE |
dc.title.alternative | Mortalidad en melanoma maligno cutáneo y su asociación con la relación neutrófilos a linfocitos | es_PE |
dc.type | info:eu-repo/semantics/article | es_PE |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.21 | es_PE |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.15 | es_PE |
dc.identifier.doi | https://doi.org/10.1016/j.ctarc.2021.100464 | |